M. Elaine Husni

M. Elaine Husni

Auto-generated profile, based on publicly available information

M. Elaine Husni

Department of Rheumatic and Immunologic Diseases Cleveland Clinic Cleveland Ohio

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Permanente Journal
Verified
Journal Article
Closed access
MLMichelle J Lespasio
Michelle J Lespasio
NPNicolas S. Piuzzi
Nicolas S. Piuzzi
MHM Elaine Husni
M Elaine Husni
GMGeorge F Muschler
George F Muschler
AGAj Guarino
Aj Guarino
MMMichael A Mont
Michael A Mont
The Permanente Journal is a peer-reviewed journal of medical science, social science in medicine, and medical humanities.

1 March 2018 in The Permanente Journal
Verified
Journal Article
Closed access
MLMichelle J Lespasio
Michelle J Lespasio
ASAssem A Sultan
Assem A Sultan
NPNicolas S. Piuzzi
Nicolas S. Piuzzi
AKAnton Khlopas
Anton Khlopas
MHM Elaine Husni
M Elaine Husni
MMMichael A Mont
Michael A Mont
The Permanente Journal advances knowledge in scientific research, clinical medicine, and innovative health care delivery. Sponsored by the National Permanente Medical Groups, The Permanente Journal is a peer-reviewed journal of medical science, social science in medicine, and medical humanities. The Permanente Journal (ISSN 1552-5767) is published quarterly by The Permanente Press. The Permanente Journal is available online (ISSN 1552-5775) at www.thepermanentejournal.org. Physicians may earn up to 1 AMA PRA Category 1 Credit per article for reading and analyzing the designated CME articles published in each edition of TPJ. Each edition has four articles available for review. Other clinicians for whom CME is acceptable in meeting educational requirements may report up to four hours of participation. The Permanente Journal welcomes requests for reprints and reproduction. Use of any and all material published in The Permanente Journal is copyrighted and protected. The Permanente Journal offers free full-text access for all online content. Use as a handout, reprinting, republishing, adapting, or any other use, requires permission.

1 December 2017 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
MHM. Elaine Husni
M. Elaine Husni
JMJoseph F. Merola
Joseph F. Merola
SDSara Davin
Sara Davin
To assess the psychosocial impact of psoriatic arthritis (PsA), describe how health-related quality of life (QoL) is affected in patients with PsA, discuss measures used to evaluate the psychosocial impact of PsA, and review studies examining the effect of therapy on QoL. A targeted review on the impact of PsA on QoL and the role of tailored psychosocial management in reducing the psychosocial burden of the disease was performed. PubMed literature searches were conducted using the terms PsA, psychosocial burden, QoL, and mood/behavioral changes. Articles were deemed relevant if they presented information regarding the psychosocial impact of PsA, methods used to evaluate these impacts, or ways to manage/improve management of PsA and its resulting comorbidities. The findings of this literature search are descriptively reviewed and the authors׳ expert opinion on their interpretation is provided. The psychosocial burden of PsA negatively affects QoL. Patients suffer from sleep disorders, fatigue, low-level stress, depression and mood/behavioral changes, poor body image, and reduced work productivity. Additionally, each patient responds to pain differently, depending on a variety of psychological factors including personality structure, cognition, and attention to pain. Strategies for evaluating the burdens associated with PsA and the results of properly managing patients with PsA are described. PsA is associated with a considerable psychosocial burden and new assessment tools, specific to PsA, have been developed to help quantify this burden in patients. Future management algorithms of PsA should incorporate appropriate assessment and management of psychological and physical concerns of patients. Furthermore, patients with PsA should be managed by a multidisciplinary team that works in coordination with the patient and their family or caregivers.

1 November 2015 in Rheumatic Disease Clinics of North America
Verified
Journal Article
Closed access
MHM. Elaine Husni
M. Elaine Husni

1 May 2007
Verified
Journal Article
Closed access
DGDafna D Gladman
Dafna D Gladman
PMPhilip J Mease
Philip J Mease
VSVibeke Strand
Vibeke Strand
PHPaul Healy
Paul Healy
PHPhilip S Helliwell
Philip S Helliwell
JZJane Zochling
Jane Zochling

1 November 2014 in The Journal of Rheumatology
Verified
Journal Article
Closed access
AOAlexis Ogdie
Alexis Ogdie
SSSergio Schwartzman
Sergio Schwartzman
LELihi Eder
Lihi Eder
AMAjesh B. Maharaj
Ajesh B. Maharaj
DZDevy Zisman
Devy Zisman
EHElaine Husni
Elaine Husni
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis that can lead to decreased health-related quality of life and permanent joint damage leading to functional decline. In addition to joint and skin manifestations, both psoriasis and PsA are associated with numerous comorbidities and extraarticular/cutaneous manifestations, which may influence the physician’s choice of therapy. The objectives of this review are (1) to identify comorbidities in patients with PsA based on the available evidence; (2) to examine the effects of these comorbidities or extraarticular/cutaneous manifestation on the management of patients with PsA as well as the selection of therapy; and (3) to highlight research needs around comorbidities and treatment paradigms. This review is part of a treatment recommendations update initiated by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).